Heart-Saving pills? diabetes drugs tested to shield breast cancer patients from chemo damage
NCT ID NCT07436663
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether two types of diabetes medications—SGLT2 inhibitors and DPP-4 inhibitors—can prevent heart damage caused by the chemotherapy drug doxorubicin in women with breast cancer. About 150 Egyptian women will be randomly assigned to receive one of the drugs or standard care alongside their chemo. The goal is to see if these drugs help keep the heart pumping strongly and reduce the risk of heart failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?